379 related articles for article (PubMed ID: 30102512)
1. Chemical Structure and Composition of Major Glycans Covalently Linked to Therapeutic Monoclonal Antibodies by Middle-Down Nuclear Magnetic Resonance.
Peng J; Patil SM; Keire DA; Chen K
Anal Chem; 2018 Sep; 90(18):11016-11024. PubMed ID: 30102512
[TBL] [Abstract][Full Text] [Related]
2. Minor N-Glycan Mapping of Monoclonal Antibody Therapeutics Using Middle-Down NMR Spectroscopy.
Zhuo Y; Keire DA; Chen K
Mol Pharm; 2021 Jan; 18(1):441-450. PubMed ID: 33305950
[TBL] [Abstract][Full Text] [Related]
3. Comparison of orthogonal chromatographic and lectin-affinity microarray methods for glycan profiling of a therapeutic monoclonal antibody.
Cook MC; Kaldas SJ; Muradia G; Rosu-Myles M; Kunkel JP
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Aug; 997():162-78. PubMed ID: 26114652
[TBL] [Abstract][Full Text] [Related]
4. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins.
Liu L
J Pharm Sci; 2015 Jun; 104(6):1866-1884. PubMed ID: 25872915
[TBL] [Abstract][Full Text] [Related]
5. Assessment of monoclonal antibody glycosylation: a comparative study using HRMS, NMR, and HILIC-FLD.
Shipman J; Karfunkle M; Zhu H; Zhuo Y; Chen K; Patabandige M; Wu D; Oyugi M; Kerr R; Yang K; Rogstad S
Anal Bioanal Chem; 2024 May; 416(13):3127-3137. PubMed ID: 38580890
[TBL] [Abstract][Full Text] [Related]
6. Effects of terminal galactose residues in mannose α1-6 arm of Fc-glycan on the effector functions of therapeutic monoclonal antibodies.
Aoyama M; Hashii N; Tsukimura W; Osumi K; Harazono A; Tada M; Kiyoshi M; Matsuda A; Ishii-Watabe A
MAbs; 2019 Jul; 11(5):826-836. PubMed ID: 30990348
[TBL] [Abstract][Full Text] [Related]
7. Mapping monoclonal antibody structure by 2D 13C NMR at natural abundance.
Arbogast LW; Brinson RG; Marino JP
Anal Chem; 2015 Apr; 87(7):3556-61. PubMed ID: 25728213
[TBL] [Abstract][Full Text] [Related]
8. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: Mass spectrometric methods.
Reusch D; Haberger M; Falck D; Peter B; Maier B; Gassner J; Hook M; Wagner K; Bonnington L; Bulau P; Wuhrer M
MAbs; 2015; 7(4):732-42. PubMed ID: 25996192
[TBL] [Abstract][Full Text] [Related]
9. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms.
Wada R; Matsui M; Kawasaki N
MAbs; 2019; 11(2):350-372. PubMed ID: 30466347
[TBL] [Abstract][Full Text] [Related]
10. Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles--part 1: separation-based methods.
Reusch D; Haberger M; Maier B; Maier M; Kloseck R; Zimmermann B; Hook M; Szabo Z; Tep S; Wegstein J; Alt N; Bulau P; Wuhrer M
MAbs; 2015; 7(1):167-79. PubMed ID: 25524468
[TBL] [Abstract][Full Text] [Related]
11. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro.
Hodoniczky J; Zheng YZ; James DC
Biotechnol Prog; 2005; 21(6):1644-52. PubMed ID: 16321047
[TBL] [Abstract][Full Text] [Related]
12. Quantitative glycan profiling of normal human plasma derived immunoglobulin and its fragments Fab and Fc.
Anumula KR
J Immunol Methods; 2012 Aug; 382(1-2):167-76. PubMed ID: 22683540
[TBL] [Abstract][Full Text] [Related]
13. Glycan profiling of proteins using lectin binding by Surface Plasmon Resonance.
Wang W; Soriano B; Chen Q
Anal Biochem; 2017 Dec; 538():53-63. PubMed ID: 28947169
[TBL] [Abstract][Full Text] [Related]
14. Antibody Fucosylation Lowers the FcγRIIIa/CD16a Affinity by Limiting the Conformations Sampled by the N162-Glycan.
Falconer DJ; Subedi GP; Marcella AM; Barb AW
ACS Chem Biol; 2018 Aug; 13(8):2179-2189. PubMed ID: 30016589
[TBL] [Abstract][Full Text] [Related]
15. 2D (1)H(N), (15)N Correlated NMR Methods at Natural Abundance for Obtaining Structural Maps and Statistical Comparability of Monoclonal Antibodies.
Arbogast LW; Brinson RG; Formolo T; Hoopes JT; Marino JP
Pharm Res; 2016 Feb; 33(2):462-75. PubMed ID: 26453189
[TBL] [Abstract][Full Text] [Related]
16. Assessing Fc glycan heterogeneity of therapeutic recombinant monoclonal antibodies using NP-HPLC.
Raju TS
Methods Mol Biol; 2013; 988():169-80. PubMed ID: 23475719
[TBL] [Abstract][Full Text] [Related]
17. Metabolic control of recombinant monoclonal antibody N-glycosylation in GS-NS0 cells.
Hills AE; Patel A; Boyd P; James DC
Biotechnol Bioeng; 2001 Oct; 75(2):239-51. PubMed ID: 11536148
[TBL] [Abstract][Full Text] [Related]
18. Impact of Fc N-linked glycans on in vivo clearance of an immunoglobulin G1 antibody produced by NS0 cell line.
Kim J; Luo H; White W; Rees W; Venkat R; Albarghouthi M
MAbs; 2020; 12(1):1844928. PubMed ID: 33171078
[TBL] [Abstract][Full Text] [Related]
19. Application of a Quantitative LC-MS Multiattribute Method for Monitoring Site-Specific Glycan Heterogeneity on a Monoclonal Antibody Containing Two N-Linked Glycosylation Sites.
Wang T; Chu L; Li W; Lawson K; Apostol I; Eris T
Anal Chem; 2017 Mar; 89(6):3562-3567. PubMed ID: 28199092
[TBL] [Abstract][Full Text] [Related]
20. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
